Skip to content
  • About
  • Contact
  • Contribute
  • Book
  • Careers
  • Podcast
  • Recommended
  • Speaking
  • All
  • Physician
  • Practice
  • Policy
  • Finance
  • Conditions
  • .edu
  • Patient
  • Meds
  • Tech
  • Social
  • Video
    • All
    • Physician
    • Practice
    • Policy
    • Finance
    • Conditions
    • .edu
    • Patient
    • Meds
    • Tech
    • Social
    • Video
    • About
    • Contact
    • Contribute
    • Book
    • Careers
    • Podcast
    • Recommended
    • Speaking

Allow patients to continue their opioid of choice while starting microdoses of buprenorphine

Julie Craig, MD
Meds
June 16, 2022
Share
Tweet
Share

Twenty-six hours into the shakes, sweats, crawling anxiety, and gripping nausea of opioid withdrawal, Faye caves in and takes a couple of fentanyl tabs. She knows that she must tough out a couple of days without fentanyl to start Suboxone (buprenorphine/naloxone) through a medication-assisted treatment program, but the sickness gets the better of her. Those couple of tablets reset the clock on her withdrawal.

Starting buprenorphine – an evidence-based lifesaver for opioid-dependent individuals – traditionally requires a substantial withdrawal period so that the tightly binding partial agonist does not quickly displace the pure opioid and cause sudden severe precipitated withdrawal. However, as far back as 2010, researchers in Switzerland experimented with a technique that came to be known as the Bernese method, where patients continue their opioid of choice while starting microdoses of buprenorphine that gradually increase over the span of a week, eventually displacing the opioid and leaving the patient on buprenorphine alone.

As fentanyl arises as a cheap replacement for bulkier products like oxycodone and heroin, this method has become ever more crucial as many patients are simply unable to tolerate fentanyl withdrawal long enough to initiate even a couple of milligrams of buprenorphine. Microdosing induction allows people to start buprenorphine while continuing their lives without stigmatizing interruptions to work, school, childcare, and life at large that are often caused by the opioid withdrawal period. It is entirely possible that forcing people through prolonged withdrawals to start buprenorphine was never necessary, perhaps even a needlessly cruel barrier to those trying to enter into recovery. Microdosing induction might have been the better tactic all along.

At the same time, microdosing induction to buprenorphine underlines a contradiction inherent in drug war-era rules and regulations. While avoiding the intensive withdrawal period, this induction technique requires that individuals continue their opioid of choice for approximately seven days while titrating buprenorphine to an effective dose. Unless the patient has an opioid prescription for pain, these continued opioids must come from illicit sources due to a law called the Harrison Narcotics Tax Act. The mundane language of the act – that doctors only prescribe opioids within the course of their usual practice – was interpreted by courts to mean that doctors could not prescribe opioids to assist an addicted patient, as addiction was not classified as a disease but a moral failing and thus not within the physician’s purview. As such, American physicians cannot prescribe safe, pharmaceutical-grade opioids to assist patients during the seven-day microdose transition to buprenorphine. Patients must secure their own opioids, which raises predictable barriers: paying to obtain more illicit opioids when individuals may have diverted funds to pay for treatment itself, reaching out to a dealer they have already tried to dislodge from their lives, engaging in the triggering behavior of continuing illicit substances when they have decided to quit, and risking overdose from an increasingly unpredictable and contaminated street supply.

This legal framework arose before nearly all modern understandings of substance use disorders, predating the founding of Alcoholics Anonymous by two decades, preceding the approval of methadone for opioid use disorder (OUD) by thirty years, and antedating the legal approval to use buprenorphine in the treatment of OUD by over eighty years. Indeed, the foundational legal structure under which addiction medicine operates today was passed by congress the same year that Archduke Franz Ferdinand was assassinated on the streets of Sarajevo.

Compounding the problematic legacy of the 1914 law is the comparatively youthful Controlled Substances Act, passed under President Nixon’s guidance in 1970. Among its crowning achievements is the classification of cannabis as a Schedule I substance “with no currently accepted medical use and a high potential for abuse,” setting the stage for the mass incarceration wave that continues today even as a plurality of states moves to legalize the substance. To write buprenorphine, providers are granted an exception to the Controlled Substance Act with the “X-waiver,” a bureaucratic innovation that simultaneously defies the spirit of the Harrison Act and limits buprenorphine provision to a set number of patients per provider in a manner never applied to problematic substances like prescribed benzos and stimulants.

Under a saner and more humane legal regime, Faye (a fictional composite of everyday cases) would enter into treatment with a provider who can assess her current dose and then prescribe sufficient pharmaceutical-grade oral opioids under close supervision to stave off withdrawals. Microdoses of buprenorphine would be initiated and cautiously increased over whatever time period is needed for the buprenorphine to exert its dominance at the opioid receptor while she remains comfortably free from withdrawal symptoms. To accomplish this humane end, American drug policy would require a revamp that honors a hundred years of discovery on the biochemistry of receptor-ligand dyads, the neurobiology of adverse childhood events, and the innovation of statistical methods to evaluate evidence and formulate best-practice recommendations. Most of all, Americans deserve the freedom and autonomy to choose the medical pathway most appropriate to their needs without the punishing risk of overdose while making the transition to recovery.

Julie Craig is an addiction medicine specialist.

Image credit: Shutterstock.com

Prev

Virtual care is convenient, but is it better for everyone? [PODCAST]

June 15, 2022 Kevin 0
…
Next

Is there more to patient safety than preventing medical error?

June 16, 2022 Kevin 0
…

Tagged as: Pain Management

Post navigation

< Previous Post
Virtual care is convenient, but is it better for everyone? [PODCAST]
Next Post >
Is there more to patient safety than preventing medical error?

ADVERTISEMENT

ADVERTISEMENT

ADVERTISEMENT

More by Julie Craig, MD

  • The real story of Xylazine contamination in street fentanyl and how we can manage it

    Julie Craig, MD
  • Telemedicine in the opioid crisis: a game-changer threatened by DEA regulations

    Julie Craig, MD
  • The promises and limits of a fentanyl vaccine

    Julie Craig, MD

Related Posts

  • Cutting the red tape with buprenorphine treatment for opioid use disorder

    Christina Kinnevey, MD
  • Are patients using social media to attack physicians?

    David R. Stukus, MD
  • Doctors and patients continue to search through the overgrown forest of corporate health care

    Michele Luckenbaugh
  • Don’t let the opioid crisis affect the treatment course for your patients

    T.J. Matsumoto, PA-C
  • You are abandoning your patients if you are not active on social media

    Pat Rich
  • Do we really have a choice in health care?

    Cary Fitchmun, MD

More in Meds

  • Why retail pharmacies are the future of diverse clinical trials

    Shelli Pavone
  • Why does rifaximin cost 95 percent more in the U.S. than in Asia?

    Jai Kumar, MD, Brian Nohomovich, DO, PhD and Leonid Shamban, DO
  • A world without antidepressants: What could possibly go wrong?

    Tomi Mitchell, MD
  • The truth about GLP-1 medications for weight loss: What every patient should know

    Nisha Kuruvadi, DO
  • The hidden bias in how we treat chronic pain

    Richard A. Lawhern, PhD
  • Biologics are not small molecules: the case for pre-allergy testing in an era of immune-based therapies

    Robert Trent
  • Most Popular

  • Past Week

    • Why removing fluoride from water is a public health disaster

      Steven J. Katz, DDS | Conditions
    • When did we start treating our lives like trauma?

      Maureen Gibbons, MD | Physician
    • Why male fertility needs to be part of every health conversation

      Hoag Memorial Hospital Presbyterian | Conditions
    • How home-based AI can reduce health inequities in underserved communities [PODCAST]

      The Podcast by KevinMD | Podcast
    • Inside human trafficking: a guide to recognizing and preventing it [PODCAST]

      The Podcast by KevinMD | Podcast
    • Graduating from medical school without family: a story of strength and survival

      Anonymous | Education
  • Past 6 Months

    • Why tracking cognitive load could save doctors and patients

      Hiba Fatima Hamid | Education
    • What the world must learn from the life and death of Hind Rajab

      Saba Qaiser, RN | Conditions
    • The silent toll of ICE raids on U.S. patient care

      Carlin Lockwood | Policy
    • My journey from misdiagnosis to living fully with APBD

      Jeff Cooper | Conditions
    • Addressing the physician shortage: How AI can help, not replace

      Amelia Mercado | Tech
    • Why does rifaximin cost 95 percent more in the U.S. than in Asia?

      Jai Kumar, MD, Brian Nohomovich, DO, PhD and Leonid Shamban, DO | Meds
  • Recent Posts

    • How home-based AI can reduce health inequities in underserved communities [PODCAST]

      The Podcast by KevinMD | Podcast
    • Adriana Smith’s story: a medical tragedy under heartbeat laws

      Nicole M. King, MD | Physician
    • What if medicine had an exit interview?

      Lynn McComas, DNP, ANP-C | Conditions
    • Why U.S. health care pricing is so confusing—and how to fix it

      Ashish Mandavia, MD | Physician
    • From survival to sovereignty: What 35 years in the ER taught me about identity, mortality, and redemption

      Kenneth Ro, MD | Physician
    • When doctors forget how to examine: the danger of lost clinical skills

      Mike Stillman, MD | Physician

Subscribe to KevinMD and never miss a story!

Get free updates delivered free to your inbox.


Find jobs at
Careers by KevinMD.com

Search thousands of physician, PA, NP, and CRNA jobs now.

Learn more

Leave a Comment

Founded in 2004 by Kevin Pho, MD, KevinMD.com is the web’s leading platform where physicians, advanced practitioners, nurses, medical students, and patients share their insight and tell their stories.

Social

  • Like on Facebook
  • Follow on Twitter
  • Connect on Linkedin
  • Subscribe on Youtube
  • Instagram

ADVERTISEMENT

ADVERTISEMENT

ADVERTISEMENT

ADVERTISEMENT

  • Most Popular

  • Past Week

    • Why removing fluoride from water is a public health disaster

      Steven J. Katz, DDS | Conditions
    • When did we start treating our lives like trauma?

      Maureen Gibbons, MD | Physician
    • Why male fertility needs to be part of every health conversation

      Hoag Memorial Hospital Presbyterian | Conditions
    • How home-based AI can reduce health inequities in underserved communities [PODCAST]

      The Podcast by KevinMD | Podcast
    • Inside human trafficking: a guide to recognizing and preventing it [PODCAST]

      The Podcast by KevinMD | Podcast
    • Graduating from medical school without family: a story of strength and survival

      Anonymous | Education
  • Past 6 Months

    • Why tracking cognitive load could save doctors and patients

      Hiba Fatima Hamid | Education
    • What the world must learn from the life and death of Hind Rajab

      Saba Qaiser, RN | Conditions
    • The silent toll of ICE raids on U.S. patient care

      Carlin Lockwood | Policy
    • My journey from misdiagnosis to living fully with APBD

      Jeff Cooper | Conditions
    • Addressing the physician shortage: How AI can help, not replace

      Amelia Mercado | Tech
    • Why does rifaximin cost 95 percent more in the U.S. than in Asia?

      Jai Kumar, MD, Brian Nohomovich, DO, PhD and Leonid Shamban, DO | Meds
  • Recent Posts

    • How home-based AI can reduce health inequities in underserved communities [PODCAST]

      The Podcast by KevinMD | Podcast
    • Adriana Smith’s story: a medical tragedy under heartbeat laws

      Nicole M. King, MD | Physician
    • What if medicine had an exit interview?

      Lynn McComas, DNP, ANP-C | Conditions
    • Why U.S. health care pricing is so confusing—and how to fix it

      Ashish Mandavia, MD | Physician
    • From survival to sovereignty: What 35 years in the ER taught me about identity, mortality, and redemption

      Kenneth Ro, MD | Physician
    • When doctors forget how to examine: the danger of lost clinical skills

      Mike Stillman, MD | Physician

MedPage Today Professional

An Everyday Health Property Medpage Today
  • Terms of Use | Disclaimer
  • Privacy Policy
  • DMCA Policy
All Content © KevinMD, LLC
Site by Outthink Group

Leave a Comment

Comments are moderated before they are published. Please read the comment policy.

Loading Comments...